NLC Health Ventures

NLC operates through a management team and supervisory board drawn from its 40-plus professionals; however, the firm does not publicly name a single CIO or managing partner with sole investment authority. Strategic investor Boudewijn Poelmann sits on the supervisory board, and venture partners oversee portfolio company performance. The firm's website emphasizes collective decision-making across its fund management and enabling teams.

NLC operates exclusively through direct company creation and does not participate in third-party fund commitments. It builds ventures internally, then deploys capital via captive vehicles like the NLC Health Impact Fund. This model gives NLC full control over investment terms, board composition, and operational strategy from incorporation onward.

NLC focuses on very early-stage healthtech: pre-seed, seed, and Series A rounds for companies it has built from academic intellectual property. The firm occasionally supports growth-stage follow-ons within its existing portfolio but does not pursue late-stage or pre-IPO opportunities outside its own venture creation pipeline.

NLC does not source deals in the traditional venture capital sense — it originates proprietary pipeline by identifying under-commercialized medical patents at universities and research hospitals, then builds startups around them. This academic-sourcing model, combined with a network of over 1,000 subject-matter experts, provides a funnel that is independent of broker or matchmaking platforms.

NLC's portfolio concentrates on cardiovascular, orthopedics, spine, therapeutics, and AI-enabled diagnostics. The firm's published materials do not indicate activity in pure software-as-a-service, fintech, defense, or consumer internet companies. Its mandate is strictly health technology with a path to regulatory approval or CE marking.